Evidence map›Paper›PMID 39897807›Full record

ArticleHeliyon2025

Amaka Cecilia Agbara, Ejike Daniel Eze, Christian Emeka Offor, Adam Moyosore Afodun, Ezebuilo Ugbala Ekpono, Peter Chinedu Agu, Chinyere Aloke, Nkeiru Nwaamaka Ezeani, Emmanuel Orire Ikuomola, Ekom Monday Etukudo and 3 more

Abstract read
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amaka Cecilia AgbaraDepartment of Biochemistry, Faculty of Science, Ebonyi State University, Abakaliki, Nigeria.
Ejike Daniel EzeDepartment of Physiology, School of Medicine, Kabale University, Kabale, Uganda.
Christian Emeka OfforDepartment of Biochemistry, Faculty of Science, Ebonyi State University, Abakaliki, Nigeria.
Adam Moyosore AfodunDepartment of Anatomy and Cell Biology, Faculty of Health Sciences, Busitema University, Uganda.
Ezebuilo Ugbala EkponoDepartment of Science Laboratory Technology, Biochemistry Option, Federal Polytechnic Oko, Anambra State, Nigeria.
Peter Chinedu AguDepartment of Biochemistry, Faculty of Science, Ebonyi State University, Abakaliki, Nigeria.
Chinyere AlokeDepartment of Medical Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, Alex-Ekwueme Federal University, Ndufu-Alike, Ikwo, Ebonyi State, Nigeria.
Nkeiru Nwaamaka EzeaniDepartment of Biochemistry, Faculty of Science, Ebonyi State University, Abakaliki, Nigeria.
Emmanuel Orire IkuomolaDepartment of Physiology, Faculty of Biomedical Sciences, Kampala International University, Uganda.
Ekom Monday EtukudoDepartment of Human Anatomy, Faculty of Biomedical Sciences, Kampala International University, Uganda.
Ilemobayo Victor FasogbonDepartment of Biochemistry, Faculty of Biomedical Sciences, Kampala International University, Uganda.
Angela Mumbua MusyokaDepartment of Biochemistry, Faculty of Biomedical Sciences, Kampala International University, Uganda.
Patrick Maduabuchi AjaDepartment of Biochemistry, Faculty of Science, Ebonyi State University, Abakaliki, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to determine whether C. mannii seed oil (CMSO) could shield rats from cyclophosphamide-induced hepatorenal toxicity. The focus was on its antioxidant and anti-inflammatory properties. We randomly assigned thirty-six (36) male Wistar rats into six groups of six rats each. Groups A and B served as normal and negative controls, respectively. Group C, the standard control, was administered 300 mg/kg body weight (bw) of Omega 3 oil for 27 days, followed by 100 mg/kg bw of cyclophosphamide on day 28. Group D, E, and F received 5, 2.5, and 1.5 ml/kg b.w. of CMSO for 27 days, then 100 ml/kg b.w. of cyclophosphamide on day 28. We measured the body weights of the experimental rats every week. Rats of all groups were sacrificed on day 30 and collected blood for biochemical analysis using standard methods. The phytochemical constituents were determined by the spectrophotometric method. The phytochemical study of CMSO indicated the relative composition of constituents(mg/100g) as phenols (30 %), tannins (20 %), flavonoids (18 %), terpenoids (15 %), glycosides (10 %), alkaloids (5 %), and HCN (2 %) in Cucumeropsis mannii seed oil. When cyclophosphamide was given to Wistar albino rats, it greatly decreased the activities of catalase (CAT) and superoxide dismutase (SOD), but it increased the activities of iNOS and the levels of MDA and IL-1β. Cyclophosphamide increased ALT (52.3 U/L), AST (48.7 U/L), ALP (46.5 U/L), total bilirubin (1.4 mg/dL), conjugated bilirubin (0.8 mg/dL), creatinine (0.8 mg/dL), urea (45.6 mg/dL), and BUN (15.7 mg/dL), with a reduction in the albumin (4.8 g/dL) level. Cyclophosphamide administration also caused hepatocellular necrosis, inflammatory leukocyte infiltration, tubular necrosis, and proteinaceous deposits in Bowman's space in the kidney. However, combining CMSO and Omega 3 oils significantly restored the altered histology architecture, antioxidant, inflammatory markers, and liver and kidney function parameters to levels comparable to the normal group, thereby reducing the harmful effects of cyclophosphamide. This effect did not depend on the dose. These results suggest that CMSO, being an antioxidant and an anti-inflammatory, could potentially aid in preventing and treating hepatorenal toxicity resulting from cyclophosphamide.

Indexed as

C. mannii seed oilcyclophosphamideLiver and kidney toxicityProphylactic efficacy

Identifiers

PMID39897807
PMCPMC11783392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.